Outset Medical Inc (OM)
2.84
+0.31
(+12.25%)
USD |
NASDAQ |
May 01, 16:00
2.86
+0.02
(+0.70%)
After-Hours: 20:00
Outset Medical Research and Development Expense (Quarterly): 12.53M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 12.53M |
| September 30, 2023 | 16.08M |
| June 30, 2023 | 14.91M |
| March 31, 2023 | 13.79M |
| December 31, 2022 | 11.44M |
| September 30, 2022 | 13.06M |
| June 30, 2022 | 13.52M |
| March 31, 2022 | 10.83M |
| December 31, 2021 | 11.41M |
| Date | Value |
|---|---|
| September 30, 2021 | 9.729M |
| June 30, 2021 | 8.032M |
| March 31, 2021 | 7.57M |
| December 31, 2020 | 7.784M |
| September 30, 2020 | 9.175M |
| June 30, 2020 | 6.053M |
| March 31, 2020 | 5.838M |
| December 31, 2019 | 6.629M |
| September 30, 2019 | 5.708M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
5.708M
Minimum
Sep 2019
16.08M
Maximum
Sep 2023
10.23M
Average
10.28M
Median
Research and Development Expense (Quarterly) Benchmarks
| AngioDynamics Inc | 8.189M |
| Baxter International Inc | 172.00M |
| Allurion Technologies Inc | 6.071M |
| Perspective Therapeutics Inc | 6.08M |
| Xtant Medical Holdings Inc | 0.492M |